TrialNature communications2021

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).

Elizabeth M Swisher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.